The purpose of this study is to determine whether an experimental drug called sotagliflozin is effective in treating symptoms related to hypertrophic cardiomyopathy (HCM). HCM is a common heart condition that causes the heart muscle to thicken and can trigger irregular heartbeats and heart failure. Sotagliflozin controls blood sugar by slowing gut absorption and boosting helpful hormones. In the kidneys, it blocks glucose (blood sugar), leading to calorie loss and potentially lowering blood pressure; this may indirectly ease heart stress. Thus, the drug can potentially be used for HCM treatment. In addition to examining whether sotagliflozin is effective in treating HCM-related symptoms, researchers will evaluate how well the drug is tolerated and its side effects. Study procedures include echocardiograms, ECGs, questionnaires, and blood/urine testing. Participants will be randomly assigned by chance to receive either sotagliflozin or placebo (inactive substance). Sotagliflozin is approved by the U.S. Food and Drug Administration (FDA) for a heart failure related indication; however, its use is considered experimental in this study of patients with hypertrophic cardiomyopathy.
What is the full name of this clinical trial?
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy